July 14, 2025

Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

MAIN FINDING: p-H2AX serves as a pharmacodynamic biomarker for TP-0903 treatment in AML patients.
KEY EVIDENCE: Changes in p-H2AX were measured at baseline and day 10 in patients achieving complete remissions.
APPROACH: Spectral flow cytometry analyzed peripheral blood samples to assess p-H2AX levels over time.
SIGNIFICANCE: Identifying p-H2AX as a reliable biomarker may enhance treatment monitoring in acute myeloid leukemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Phase 1b/2 trial shows changes in p-H2AX levels in acute myeloid leukemia patients, highlighting potential pharmacodynamic markers for therapy.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 1b/2 trial shows changes in p-H2AX levels in acute myeloid leukemia patients, highlighting potential pharmacodynamic markers for therapy.